Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030406 · ClinicalTrials.gov registry record · Phase 2
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
A Phase 2 study, sponsored by Acura Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01030406: Completed Phase 2 study, sponsored by Acura Pharmaceuticals.
NCT01030406 is a Phase 2 study that has completed, run by Acura Pharmaceuticals. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030406, a Phase 2 study, has completed, sponsored by Acura Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
Primary Outcome
Drug Liking/Disliking Assessment on a 101 point bipolar visual analog scale (VAS) used to assess response to the question "Do you dislike or like the drug effect you are feeling now?" and anchored in the center with "Neither like nor dislike" (score of 50), on the left with "Dislike an awful lot" (score of 0) and on the right with "Like an awful lot" (score of 100).
Interventions
- DRUG 40/0mg taken first
- DRUG 80/0mg taken first
- DRUG 40/240mg taken first
- DRUG 80/480mg taken first
- DRUG 0/0mg taken first
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT01030406 record still lists
NCT01030406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 5 interventions - of which 40/0mg taken first is the first listed.
NCT01030406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01030406 about?
NCT01030406 is a clinical study titled "Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users". The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
What is the current status of trial NCT01030406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2010-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT01030406?
The interventions under investigation include: 40/0mg taken first (DRUG), 80/0mg taken first (DRUG), 40/240mg taken first (DRUG), 80/480mg taken first (DRUG), 0/0mg taken first (DRUG).
Who is sponsoring clinical trial NCT01030406?
This trial is sponsored by Acura Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01030406's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia